Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.
Teva Pharmaceutical Industries Ltd. is launching the first alternative version of the emergency allergy medicine EpiPen (epinephrine) outside of Mylan's brand and authorized generics, but the cost will be the same. The wholesale acquisition cost of Teva's generic is $300 for a two-pack, the same WAC as Mylan's authorized generic.
It looks like it might take more competition on the market to lower the price, or perhaps competitive rebating, though...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
